Short interview today with LDX CEO on the FY21 rev increase + OEM partner EUA approval in US market. Nothing new shared.
CEO reiterated near-term focus continues to be scaling up US production chain, FebriDx commercialisation and overall capacity
+
a short article where LDX is mentioned:
2 Aug'21 - Who’s winning and losing in the life sciences IPO Olympiad?
https://unauthorised investment advice/health/dr-borehams-crucible-whos-winning-and-losing-in-the-life-sciences-ipo-olympiad/ (remove * in link)
"Only two weeks earlier Lumos Diagnostics (ASX:LDX) listed on the back of its fingerprick blood test to diagnose respiratory diseases. Lumos shares have held their ground, valuing the company at a cool $187 million.
As has been the experience with IPOs more broadly – and there’s been a spate of them – the only distinct trend from the Covid-era biotech listings is that there’s no distinct trend.We would like to say there’s a distinct pattern between how the drug developers have performed vis-a-vis the diagnostics or device plays, but there’s not."
Ann: Lumos Business Momentum Continues Following ASX Listing, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.001(2.33%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 3.9¢ | $100.6K | 2.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 623990 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 298309 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| LDX (ASX) Chart |